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Trehalose 6,6=-dimycolate (TDM) is a cell wall glycolipid and an important virulence factor of mycobacteria. In order to study
the role of TDM in the innate immune response toMycobacterium tuberculosis, microarray analysis was used to examine gene
regulation in murine bone marrow-derived macrophages in response to 90-m-diameter polystyrene microspheres coated with
TDM. A large number of genes, particularly those involved in the immune response andmacrophage function, were up- or
downregulated in response to these TDM-coated beads compared to control beads. Genes involved in the immune response were
specifically upregulated in a myeloid differentiation primary response gene 88 (MyD88)-dependent manner. The complexity of
the transcriptional response also increased greatly between 2 and 24 h. Matrix metalloproteinases (MMPs) were significantly
upregulated at both time points, and this was confirmed by quantitative real-time reverse transcription-PCR (RT-PCR). Using
an in vivoMatrigel granuloma model, the presence and activity of MMP-9 were examined by immunohistochemistry and in situ
zymography (ISZ), respectively. We found that TDM-coated beads inducedMMP-9 expression and activity inMatrigel granulo-
mas. Macrophages were primarily responsible for MMP-9 expression, as granulomas from neutrophil-depleted mice showed
staining patterns similar to that for wild-type mice. The relevance of these observations to human disease is supported by the
similar induction of MMP-9 in human caseous tuberculosis (TB) granulomas. Given that MMPs likely play an important role in
both the construction and breakdown of tuberculous granulomas, our results suggest that TDMmay drive MMP expression dur-
ing TB pathogenesis.
Mycobacterium tuberculosis, the causative agent of tuberculosis(TB), infects approximately one-third of the human popu-
lation and is the leading bacterial cause of human mortality world-
wide, killing 1.45 million individuals per year (1). In the majority
of cases, however, the bacteria are sequestered within a well-orga-
nized granuloma, where they can remain in a poorly character-
ized, “latent” state for decades. The granuloma structure is typi-
cally composed of centrally located, infected macrophages in
various stages of degeneration and necrosis, surrounded by epi-
thelioid macrophages, foamy macrophages, and occasional multi-
nucleated giant cells, all bordered by a mixed population of lym-
phocytes and a fibrous capsule. This capsule consists of a wall of
collagen that is laid down by fibroblasts and must be broken down
in order for transmission to occur. Infected individuals who are
immunocompetent and/or treated can resolve granulomas, with
disaggregation of the accumulated leukocytes, dissolution of the
extracellular matrix, and either scar formation or a return to the
normal pulmonary architecture. In progressively infected individ-
uals, on the other hand, the granuloma liquefies, the capsule wall
cavitates and ruptures into an adjacent airway, and the bacilli mul-
tiply and are released (2). While some causes of tuberculosis reac-
tivation are known, such as coinfection with human immunode-
ficiency virus (3), aging, chemotherapy, malignant disease,
malnutrition, and other causes of immunosuppression, in many
cases the “trigger” leading to the breakdown of the granuloma
capsule is unknown.
Trehalose 6,6=-dimycolate (TDM) is a major glycolipid present
in the cell walls of mycobacteria and other members of the order
Actinomycetales. TDM confers a cording (clumped) phenotype to
virulent mycobacterial species and has been shown to produce
many of the clinical signs and lesions associated with TB and com-
plete Freund’s adjuvant (4, 5). Intriguingly, the proinflammatory
activity of TDM is dependent upon its mode of presentation to
immune cells; larger surface areas of presentation, such as mono-
layers, emulsions, and nonphagocytosable particles, are more
stimulatory than micelles or bacterium-sized particles (6–8). His-
topathologic and microarray analyses of artificial granulomas, in-
duced in mice by the injection of TDM-coated beads admixed
with Matrigel, showed that TDM elicits foam cell formation and
regulation of some of the host lipid metabolism genes in a manner
similar to that observed in human TB granulomas (9). The exact
role of TDM in the pathogenesis of TB, however, remains to be
determined.
Matrix metalloproteinases (MMPs) are a family of zinc met-
alloendopeptidases secreted by a variety of cells that function in
the turnover of extracellular matrix components, making MMPs
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likely players in cavity formation and the breakdown of the gran-
uloma capsule. MMPs are also involved in cell migration, inter-
cellular communication, and a variety of pathological conditions
(10). The MMPs are classified into subgroups based on their struc-
ture and substrate specificities (collagenases, gelatinases, strome-
lysins, matrilysins, membrane-type MMPs, etc.). Most MMPs are
not expressed in normal healthy tissues but are expressed and
activated in tissues that are inflamed or undergoing remodeling.
MMPs can be upregulated by various exogenous stimuli, such as
bacterial components, cytokines, or cell-to-cell contact. MMP secre-
tion is regulated primarily by the prostaglandin and mitogen-acti-
vated protein kinase (MAPK) signal transduction pathways (11).
As MMPs can be highly destructive, the process of activation is
tightly regulated. First, with the exception of MMP-8 and -9, the
MMPs are not stored and require de novo gene transcription. Sec-
ond, MMPs are synthesized as zymogens and must have their
N-terminal propeptide removed by other MMPs or proteinases in
order to become active (12). Finally, there are endogenous inhib-
itors of MMP activity, such as 2-macroglobulin, as well as the
four specific tissue inhibitors of metalloproteinases (TIMPs) iden-
tified in humans to date (13), which inhibit MMP activity by bind-
ing to the catalytic site (14). MMPs may also be inactivated by
internalization or oxidation and downregulated by certain cyto-
kines, such as gamma interferon (IFN-), interleukin-4 (IL-4),
and IL-10 (15, 16).
The pulmonary parenchyma is rich in collagen types I, III, and
IV, as well as elastin. It is therefore likely that MMPs that can
cleave these fibrils are involved in tuberculosis granuloma forma-
tion, cavitation, and capsule breakdown. In mice, M. tuberculosis
infection results in increased MMP-2 and -9 (gelatinases) levels
(17, 18). In human TB studies, MMP-1 (interstitial collagenase
not present in mice), MMP-2, MMP-7 (matrilysin), MMP-8
(neutrophil elastase), and MMP-9 have been described as being
upregulated either in vitro or in vivo (19–22). Recently, the impor-
tance of MMP-1 was highlighted in a report showing that M. tu-
berculosis infection of MMP-1 transgenic mice caused more de-
structive lesions with greater similarity to TB lesions in humans
(23) than those observed in wild-type mice. Circulating levels of
MMP-9, in particular, have been shown to correlate with disease
severity in tuberculosis patients (24). MMP-9 has also been shown
in the zebrafish model to be induced by the mycobacterial viru-
lence factor 6-kDa early secreted antigenic target (ESAT6), which
plays a significant role in macrophage recruitment, granuloma
formation, and bacterial survival (25).
In this study, we used DNA microarrays to compare murine
bone marrow-derived macrophage (BMM) transcriptional
responses to TDM-coated microspheres with those to phosphati-
dylglycerol (PG)-coated microspheres or those of resting macro-
phages at early (2 h) and late (24 h) time points. The transcrip-
tional responses to TDM in mice deficient in the Toll-like receptor
(TLR) adaptor molecule myeloid differentiation primary re-
sponse gene 88 (MyD88) versus wild-type BMM responses were
also compared. These experiments revealed that many immune
response and tissue remodeling genes were upregulated in a
MyD88-dependent manner after stimulation with TDM. The
marked upregulation of MMP-8, -9, -12, -13, and -14 in response
to TDM, which was validated by real-time reverse transcription-
PCR (RT-PCR), prompted further study of these related enzymes.
A murine Matrigel-based granuloma model was used to show that
TDM induces production of MMP-8 and -9, and activation of
MMP-9 was specifically shown by in situ zymography (ISZ).
Moreover, MMP-9 was also determined, by laser capture micro-
dissection and microarray analysis, to be highly upregulated in
late-stage human TB granulomas. Based on these results, we pro-
pose that in late-stage TB granulomas, large aggregates of M. tu-
berculosis or mycobacterial lipids within the caseous core could
provide a large surface area of TDM presentation to macrophages,
stimulating them to produce and activate various MMPs, which
may in turn break down the capsule, leading to TB transmission.
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Charles River Breeding Labo-
ratories or Taconic. MyD88-deficient mice on a C57BL/6/129F2 back-
ground were generated by S. Akira (Osaka University) and generously
provided by S. Ehrt (Weill Cornell Medical College). All mice were housed
at the Cornell University Transgenic Mouse Facility under specific-patho-
gen-free conditions. All mice used in this study were between 5 and 8
weeks of age.
Human TB granulomas. Data from human tissue specimens were
mined from a previously published microarray study (9). That work was
approved by the institutional review boards at the University of Cape Town,
South Africa, the Public Health Research Institute, Newark, NJ, and Cornell
University, Ithaca, NY. Informed consent was obtained from all patients.
Macrophage culture. BMM were cultured as previously described
(8) and maintained in Dulbecco’s modified Eagle’s medium supple-
mented with L-929 cell-conditioned medium (20%), 10% heat-inacti-
vated fetal calf serum (FCS; HyClone), L-glutamine (2 mM; Gibco), so-
dium pyruvate (1 mM; Gibco), 100 U/ml penicillin (Gibco), and 100
g/ml streptomycin (Gibco).
Lipid extraction and purification.Mycobacterium bovis BCG Pasteur
orM. tuberculosisH37Rv cultures were grown in shaking liquid cultures of
Middlebrook 7H9 (Difco) or glycerol-alanine-salts (GAS) medium, re-
spectively, as previously described (8, 26). The bacilli were washed exten-
sively with phosphate-buffered saline (PBS) before extraction with chlo-
roform and methanol, fractionation, and purification as previously
described (8, 27). Purified lipid identities were confirmed by Fong Hsu at
Washington University, using electrospray ionization mass spectrometry.
Bovine-derived PG andM. tuberculosisH37Rv TDM (for some experiments)
were purchased from Sigma-Aldrich. All lipids were stored in chloroform-
methanol (2:1 [vol/vol]) at 10 mg/ml at20°C under nitrogen.
Lipid-coated microspheres. A total of 125 g of either M. bovis BCG
TDM, M. tuberculosis H37Rv TDM, or PG solubilized in chloroform-
methanol (2:1 [vol/vol]) was used to coat the surfaces of solvent-resistant
tubes. A total of 2.5 ml of a 2.5% solids solution of 90-m-diameter
polystyrene microspheres (Polysciences) for each sample was washed
twice with PBS and then coated with the lipids as previously described (8).
Lipid-coated microspheres were resuspended in 1 ml of PBS.
BMM RNA extraction. Lipid-coated microspheres were added to
60-mm-diameter dishes (non-tissue culture treated; Kord-Valmark) of
confluent BMM that had been acclimated for at least 1 h to 4 ml of fresh
warmed medium. For 2-h experiments, the medium was discarded and
immediately replaced with 4 ml of TRIzol (Invitrogen), with pipetting and
rinsing to lyse the cells completely. Lysates were immediately transferred
to solvent-resistant tubes and frozen at80°C until RNA extraction. For
24-h experiments, the medium was brought up to 10 ml 2 h after adding
the microspheres, and then the cells were lysed after 24 h as described
above. RNA was extracted using an RNeasy minikit (Qiagen) and then
treated with Turbo DNA-free DNase (Ambion) following the manufac-
turers’ instructions.
Microarray analysis. All RNA samples were submitted to the Cornell
University Core Microarray Facility for processing and microarray anal-
ysis. RNA purity and integrity were examined on an Agilent Bioanalyzer
2100. Total RNA samples were labeled using a MessageAmp II-Biotin
Enhanced Single Round aRNA amplification kit (Ambion, Austin, TX)
according to the manufacturer’s protocol. Labeled cRNA was hybridized
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on Affymetrix mouse MG430A 2.0 (or other) GeneChips, stained,
washed, and scanned by a GeneChip Scanner 3000. The raw array data
were processed by Affymetrix GCOS software to obtain detection calls and
signal values. The signals of each array were normalized by scaling to a
target value of 500, using GCOS software. Files were preprocessed with the
GC-RMA algorithm and analyzed with Genespring 7.3 (Agilent Technol-
ogies) software. Data from human TB granulomas were analyzed as pre-
viously described (9). Each microarray data set represents the averages for
three independent biological replicates with separate RNA isolation,
labeling, and array hybridization. Genes with significant changes in gene ex-
pression were identified based on a combination of fold change and P value
cutoffs and analysis of variance (ANOVA), as indicated in the text.
Real-time RT-PCR. cDNA was synthesized from 250 ng total RNA by
use of an iScript cDNA synthesis kit (Bio-Rad), using the following tem-
perature cycle: 25°C for 5 min, 42°C for 30 min, and 85°C for 5 min. iTaq
SYBR Green Super mix with ROX (Bio-Rad) was used per the manufac-
turer’s protocol, with 2l sample cDNA and a 7.2M final concentration
of primer. Relative quantitative real-time PCR was performed using an
ABI 7500 thermal cycler (Applied Biosystems) following the manufactur-
er’s protocol, with -actin as an endogenous control. Dissociation curves
were run after each assay per the manufacturer’s instructions for quality
control. Primer sequences are available upon request. All primers used
were optimized by comparing amplification efficiencies between endog-
enous controls and target RNA over a dose range. Results present the
averages for three technical replicates and are representative of three bio-
logical replicates.
Bead-based granuloma model. One hundred micrograms of M. tu-
berculosisH37Rv TDM (Sigma-Aldrich) was used to coat solvent-resistant
tubes, to which were added 2 103 90-m-diameter or 3 106 10-m-
diameter washed polystyrene microspheres suspended in 1 ml of PBS. For
immunohistochemistry (IHC)-based experiments, 107 congenic BMM
were added to this Matrigel solution, and injections were performed in-
traperitoneally (i.p.). Ninety-micrometer-diameter microspheres were
required for i.p. injections, as microspheres with smaller diameters do not
allow cohesiveness of the matrix in the peritoneal cavity. The i.p. granu-
loma model is also consistent with and comparable to our previous work
(7, 8). For ISZ experiments, cryosectioning was required, which could not
be performed with 90-m-diameter microspheres; 10-m-diameter
spheres, which have previously been shown to be immunostimulatory (8),
although less so than 90-m-diameter microspheres, were used instead,
and injections were given subcutaneously to avoid dispersal of the matrix.
Histologically, subcutaneous matrices are comparable to peritoneal ones,
as similar leukocyte populations are recruited to 10-m-diameter
spheres, in a comparable time frame. Microspheres were coated as de-
scribed previously (8), with the exception of extra sonication steps to
resuspend the 10-m-diameter coated beads after each centrifugation.
TDM-coated microspheres were then resuspended in 1 ml of growth fac-
tor-reduced Matrigel (BD Biosciences), drawn up in 1-ml TB syringes
fitted with 21-gauge needles, and kept on ice until injection. Three hun-
dred microliters of this matrix was injected per mouse. For ISZ, no
BMM were added so that only recruited leukocytes were examined for
MMP activity. At various time points, injected mice were euthanized and
the artificial granulomas were either placed in 4% paraformaldehyde
(PFA) in PBS for IHC or snap-frozen in Tissue-Tek OCT compound
(Sakura) in liquid nitrogen for ISZ. For IHC, samples were kept in 4% PFA
at 4°C for at least 24 h, transferred to 70% ethanol for at least 24 h, and
then submitted to the Histology Laboratory at the Cornell University
Diagnostic Laboratory for processing. ISZ samples were maintained at
80°C until cryosectioning.
Neutrophil depletion. An anti-Ly-6G antibody (rat IgG2b, clone
RB6-8C5) was developed by R. Coffman (DNAX Research Institute). This
antibody (RB6) depletes murine neutrophils and eosinophils as well as a
subset of macrophages in vivo (28, 29). RB6-8C5 hybridoma cells, gener-
ously provided by E. Denkers (Cornell University), were cultured in hy-
bridoma SFM (Gibco Life Technologies) in Vectracell single-use bioreac-
tors (Vectracell). Hybridoma supernatants were filtered through 0.2-m-
pore-size filters prior to storage at 4°C until RB6 antibody recovery.
Antibody was concentrated using an Amicon 8400 device (Millipore) fit-
ted with a 100-kDa exclusion membrane (Millipore-Amicon YM100 ul-
trafiltration membrane). Antibody purity was confirmed by SDS-PAGE
before further concentration using an Amicon Ultra-15 centrifugal filter
device with a nominal molecular weight limit (NMWL) of 30,000 (Milli-
pore). Antibody concentration was determined by Bradford assay (Bio-
Rad), and the antibody was resuspended at 2 mg/ml in PBS, sterile filtered,
and stored at 4°C until use. C57BL/6 mice were injected i.p. with 200g of
RB6 suspended in 100 l of PBS at intervals of 48 h until sacrifice. These
mice were injected with TDM-coated bead matrices (as described above)
48 h after the first RB6 dose. Mice were sacrificed at 14 h, 36 h, and 4 days
post-matrix injection. Depletion of neutrophils and subsets of eosinophils
and macrophages was confirmed by flow cytometry. Matrices were fixed
and processed for IHC as described above.
ISZ. Cryosections were thawed and air dried. OCT was dissolved by
incubating slides in PBS for 1 h at room temperature. Sections were pre-
incubated with ISZ buffer (ISZB; 50 mM Tris, pH 7.4, 10 mM CaCl2,
0.05% Triton X-100) with or without inhibitors for 1 h at room temper-
ature. For MMP-9, frozen aliquots of DQ-gelatin buffer (2% gelatin, 2%
sucrose, 0.02% sodium azide in PBS) and DQ-gelatin (0.025% DQ-gelatin
in buffer) were thawed at 100°C and then transferred to and maintained at
50°C until used. For other MMPs, aliquots of 1% agarose in ISZB were
thawed as described above. Inhibitors and exogenous MMPs (positive
controls) were also thawed at 50°C and used at final concentrations of 60
nM (MMP-2/9 inhibitor), 40 nM (MMP-8 inhibitor), and 0.4 mg/ml
(exogenous MMPs). Slides were dried by blotting around the section and
were warmed on a 37°C heat block. Twenty-five microliters of DQ-gelatin
or agarose mix, with or without inhibitors or exogenous MMPs, was ap-
plied to each section on the 37°C heat block and immediately coverslipped
and sealed with nail polish. Slides were maintained in the dark in a hu-
midity chamber at 37°C for 1 h (MMP-9) or 24 h (others) before being
examined by fluorescence microscopy on a Zeiss Axioskop 2 Plus micro-
scope. Images for ISZ and IHC were taken using an AxioCam camera and
Axiovision software (Zeiss). All images were obtained using the same
exposure time.
Immunohistochemistry. Paraffin-embedded sections were deparaf-
finized in xylene and rehydrated sequentially in 100%, 95%, and 70%
ethanol and then water. Endogenous peroxide was blocked by immersion
of the sections in 0.5% hydrogen peroxide in methanol for 10 min. Anti-
gen retrieval methods involved incubation with trypsin (Zymed kit) for 20
min at 37°C, followed by three 5-min washes in 0.05% Tween-PBS. Sec-
tions were blocked using 10% normal goat serum with 2 casein for 20
min at room temperature. Primary rabbit anti-mouse MMP-8 or -9 anti-
bodies or isotype control antibodies were diluted 1:50 or 1:100 in PBS with
1 casein and applied to sections for 1.5 to 2 h at 37°C. A biotinylated goat
anti-rabbit secondary antibody (Vector Laboratories) was used at 1:200 in
PBS for 20 min at room temperature, followed by streptavidin peroxidase
(Zymed) for 20 min at room temperature. Sections were developed using
AEC chromogen/substrate solution (Zymed) at room temperature for 5
to 15 min. The reaction was stopped using distilled water, and then the
sections were counterstained using Gill’s number 2 hematoxylin (Fisher)
for 30 s, rinsed under water, and mounted using Fluoromount (Fisher).
Microarray data accession numbers. The raw data from these DNA
microarray experiments have been deposited in the ArrayExpress data-
base (http://www.ebi.ac.uk/arrayexpress/) under accession numbers E-
MEXP-3815 for the MyD88 experiments and E-MEXP-3814 for all other
experiments.
RESULTS
Trehalose dimycolate induces the regulation of a unique set of
macrophage genes. While immunostimulatory effects of TDM
are well studied, a comprehensive examination of macrophage
gene regulation by TDM has not been performed. In an effort to
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understand how TDM stimulates macrophages, we examined the
regulation of genes in murine BMM in response to M. tubercu-
losis H37Rv TDM-coated, 90-m-diameter microspheres at early
(2 h) and late (24 h) time points. We compared these data with the
response to microspheres coated with phosphatidylglycerol (PG),
a relatively noninflammatory lipid, as a control for nonspecific
gene regulation induced by the phagocytosis of a lipid and expo-
sure to polystyrene microspheres. PG elicits minimal leukocyte
recruitment or cytokine production in this microsphere model
(7, 8).
Our data indicated that 125 murine genes were upregulated
over 1.5-fold (P 0.05) in response to TDM, as early as 2 h after
exposure (Fig. 1A). By 24 h, a substantial number of genes were
either upregulated (503 genes were upregulated 	1.5-fold; P 
0.05) or downregulated (162 genes were downregulated 	1.5-
fold; P 0.05) in response to H37Rv TDM (Fig. 1B). Table 1 lists
the specific genes, organized by biological process, that were up-
regulated at least 1.5-fold (P 0.05) at 2 h by TDM-coated beads
compared to PG-coated bead controls. Most of these genes are
involved in the acute inflammatory response. Very few genes were
downregulated by TDM-coated beads at 2 h, and these included
genes encoding the transcriptional regulators Mafb (v-maf mus-
culoaponeurotic fibrosarcoma oncogene family, protein B) and
Id1 (inhibitor of DNA binding 1), the endopeptidase Enc1 (ecto-
dermal-neural cortex 1), an immediate-early response 5-like gene
product, dual specificity phosphatase 6, SH3 domain binding pro-
tein 5, and thrombomodulin.
Genes upregulated at 24 h and with relevance to the immune
response are listed in Table 2, and relative up- or downregulation
of genes involved in the immune response and macrophage func-
tion between 2 and 24 h is shown in Fig. 2. Specific genes with
relevance to host responses toM. tuberculosis and that were up- or
downregulated at both 2 and 24 h are shown in Fig. 3. Intriguingly,
the macrophage receptor with collagenous structure (MARCO), a
class A scavenger receptor that we recently showed to bind and aid
in the macrophage response to TDM (30), was markedly upregu-
lated between 2 and 24 h (Fig. 3E).
Approximately 30 genes were downregulated at least 2-fold in
response to TDM-coated beads at 24 h, and genes of interest with
regard to immune responses and tissue remodeling are listed in
Table 3. Interestingly, the gene for thrombomodulin, which is a
component of the anticoagulation pathway, was the only down-
regulated gene from 2 h that continued to be downregulated at 24
h. This was not surprising, as tumor necrosis factor alpha (TNF-
), which is one of the major cytokines induced in response to
TDM (8), can inhibit thrombomodulin expression in order to
enhance coagulation during inflammatory responses (31).
While many of the genes overlapped between the two time
points, we noted distinct temporal patterns of gene expression in
response to treatment with TDM-coated beads (Fig. 2). ANOVA
comparing data from 2 h versus 24 h revealed about 450 genes
with significantly different expression levels over time (	1.5-fold;
P  0.05) (Fig. 2A). This was seen in the diverse behaviors of
early-induced genes after prolonged stimulation by TDM-coated
beads. In Fig. 1B, it is notable that while some genes induced at 2 h
(shown as black dots) remained elevated at 24 h, others returned
to control levels. By 24 h posttreatment, a subset of genes induced
at 2 h was repressed below control levels (Fig. 2B, cluster 1). There
were 51 genes exhibiting sustained upregulation (	1.5-fold; P
0.05) at both 2 and 24 h (Fig. 2B, clusters 2 and 3, and C, cluster 3).
Of these, 27 genes with sustained induction were even more highly
expressed at 24 h (Fig. 2B, cluster 3, and Table 1, asterisks), includ-
ing genes that have been shown to play a role during TB or are
induced byM. tuberculosis infection or stimulation with mycobac-
terial components, such as the genes encoding TNF- (32),
CXCL10 (IP-10) (33), Nfkbia (34), Rel-b (35), ICAM-1 (36), and
prostaglandin-endoperoxide synthase 2 (ptgs2) (37). The pre-
dominant profile encompassed a large number of genes displaying
delayed induction 24 h after exposure to TDM (Fig. 2C, clusters 1
and 2).
Transcriptional responses to TDM are predominantly
MyD88 dependent. The highly proinflammatory nature of TDM
and our previous data showing MyD88-dependent proinflamma-
tory cytokine induction by TDM-coated beads (8) prompted us to
examine differences in gene regulation between MyD88/ and
wild-type BMM in response to TDM-coated microspheres at 24
h. Negative controls in this independent set of experiments were
resting macrophages of the same genotype. Because this design did
not account for changes triggered by bead phagocytosis unrelated
to TDM, however, only genes shown in the experiment described
FIG 1 Macrophage gene regulation in response to TDM. BMM from C57BL/6 mice were stimulated with 90-m-diameter microspheres coated with TDM
purified from M. tuberculosis strain H37Rv for either 2 (A) or 24 (B) hours. Dots represent individual genes, with red indicating upregulated genes and blue
indicating downregulated genes, after normalization for gene regulation in response to PG-coated microspheres. The horizontal lines above and below 1 on the
y axis indicate our 1.5-fold cutoffs. Black dots indicate genes upregulated at 2 h that meet the criterion of a P value of0.05.
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above to be specifically up- or downregulated in response to TDM
were further analyzed. As shown in Fig. 4A, there were tremen-
dous alterations in gene expression in response to TDM-coated
beads in wild-type BMM controls. In contrast, in the absence of
TABLE 1 BMM genes upregulated in response to 90-m-diameter,
H37Rv TDM-coated beads at 2 ha
Functional category and gene product Fold change
Immune response
Cytokines
IL-1beta 5.21
IL-1rn 1.56
IL-10 1.8
MCSF-1* 1.94
TNF* 3.02
Chemokines
CCL3 2.42
CCL4 2.69
CCL7 1.82
CCL12 2.12
CCRl2* 2.01
CXCL1 4.75
CXCL2†* 3.84
CXCL10* 2.8
Others
BC008167 1.63
CD40 1.6
Clec4e* 2.27
Irf1† 1.89
Mefv* 1.8
SOD2* 1.56
Tnfsf9 2.74
Signaling
Acvr2a 1.64
Adora2b 2.29
Cav1* 1.81
Cdc42ep4 1.82
Cish 2.1
Dscr1 1.56
Dusp1 1.59
Dusp16 1.52
Dusp2 1.98
Erbb2ip 1.64
Gpr84* 3.11
Pde4b* 3.47
Pim1 2.15
Rab20* 2.07
Ralgds 1.68
Rgs16 1.63
Rgs3 1.51
Rrad 1.72
Snag1 1.55
Socs3 4.03
Spata13* 1.99
Protein modification
Herpud1 1.55
Transcription
Bcl3† 1.96
Btg2 1.6
Egr1 1.84
Egr2 1.75
Jun dimerization protein 2† 1.7
Klf7 1.94
Maff† 2.82
Nfkbia* 1.96
Nfkbie* 2.57
Nfkbiz 2.67
Prdm1 2.44
Rel 2.05
Relb* 2.01
Rpl35 1.7
Zc3h12a 1.63
TABLE 1 (Continued)
Functional category and gene product Fold change
Cell proliferation
Ets2 1.58
Gadd45b 1.91
Junb 1.83
Pdgfb 2.08
Trim13†* 2.05
Cell interactions
Icam1* 2.17
Pvr 1.69
Proteolysis
BB637972 3.23
Carboxypeptidase D 1.65
MMP13 1.72
MMP14* 2.76
Serpinb6b 1.55
Timp1 1.74
Tnfaip3 2.51
Apoptosis
Birc3 1.93
Cflar* 2.16
Cias1 2.02
Hspa1b* 2.43
Phlda1 2.1
Plagl2 1.84
Ripk2 1.54
Traf1 2.41
DNA repair
Hspa1a 2.34
Sfpq 1.78
Lipid metabolism
Ch25h 2.91
Ptgs2* 6.28
Saa3* 1.92
Angiogenesis
Qk 1.67
Tnfaip2* 1.56
Unknown
AA200306 1.57
BB183628 2.83
BC025514 1.83
BE196832 1.83
BE631223 1.8
Brd4 1.68
CD83 1.63
Errfi1 1.86
Ibrdc3* 1.73
Ier3 2.3
Irg1†* 3.19
Luc7l2 1.62
Marcksl1* 1.64
NM_138648 4.83
Nupr1 2.4
Tnip1 1.6
a Data for all upregulated genes are shown. Data for replicate genes were averaged.
Genes are listed by gene product and categorized according to predominant biological
functions with relevance to this study. Genes in common with the response to LPS at 2
h (†) and genes that continue to increase at 24 h (*) are marked.
Sakamoto et al.
768 iai.asm.org Infection and Immunity
MyD88, we observed a dramatically muted transcriptional re-
sponse to TDM (Fig. 4B). Most of the genes involved in immune
and inflammatory responses, in particular (Fig. 4, black dots),
required MyD88. Furthermore, most of the genes both up- and
downregulated in response to TDM at 24 h were also MyD88
dependent (Fig. 5). These results support our previous work
showing that TDM interacts with and signals through MARCO,
TLR2, and CD14, in a MyD88-dependent manner (30), which has
been refuted by proponents of Mincle as the TDM receptor on
macrophages (38, 39). Interestingly, key chemokines involved in
the TB response, such as CXCL1 and CCL5, were not MyD88
dependent, suggesting that TDM stimulates additional MyD88-
independent immune signaling pathways.
TDM induces marked upregulation of MMPs in macro-
phages. Upon inspection of the list of genes upregulated in wild-
type BMM in response to TDM-coated beads relative to resting
BMM, it was observed that several MMPs (MMPs 8, 9, 12, 13,
14, and 19) were markedly upregulated at 24 h, in a MyD88-
dependent manner (Fig. 6). These genes were also upregulated in
response to TDM in an experiment using cells that had been ex-
posed to PG-coated beads as a control for genes upregulated in
response to phagocytosis of a lipid, and they were all confirmed to
be upregulated by use of quantitative real-time RT-PCR (Fig. 6B).
Of the MMP inhibitors, only TIMP1 was upregulated at 2 h
(1.7-fold over the level with PG) (Table 1), but it did not stay
upregulated at 24 h. This suggests that TDM induces a shift toward
an extracellular matrix-degrading phenotype. These results
prompted us to pursue the hypothesis that TDM plays a role in the
remodeling of tissues during granuloma formation via the induc-
tion of MMPs.
TDM induces macrophage-dependent MMP-8 and -9 pro-
duction and MMP-9 activation. In order to test the hypothesis
mentioned above, paraffin-embedded sections of granulomas in-
duced in C57BL/6 mice by the injection of TDM-coated 90-m-
diameter microspheres in Matrigel (BD Biosciences) were exam-
ined by IHC for the presence of MMPs. MMP-8 was detected
primarily in macrophages in 14-hour-old matrices (Fig. 7), as
mice injected with RB6 antibody to deplete neutrophils and a
subset of inflammatory macrophages still showed strong staining
of macrophages surrounding TDM-coated beads (Fig. 7B). By 36
h, however, only scattered macrophages in the periphery of the
matrices (Fig. 7E) stained positively for MMP-8, and by 4 days
TABLE 2 BMM immune response genes upregulated at least 2-fold by
H37Rv TDM-coated beads compared to PG-coated beads at 24 ha
Immune response gene product Fold change
C3 4.77
CCRl2 3.64
Clec4e 7.11
Clec4n 4.44
Csf1 2.43
Csf2rb1 2.02
Csf2rb2 2.35
Cxcl10 6.07
Cxcl2 4.57
Gca 2.41
Icam1 2.08
Ifi35 2.38
Ifi47 2.74
Ifih1 2.47
Ifit1 4.83
Ifit2 3.58
Ifit3 5.08
IL18bp 2.25
Irf7 4.11
Irgm 2.67
Mefv 2.75
Oas1a 2.1
Oas3 3.41
Pla2g7 3.2
Relb 2.08
Sod2 3.09
Stat1 3.1
Stat2 2.98
TLR2 2.21
TNF 3.03
a Genes were categorized according to the GO biological process listings in GeneSpring
(Agilent).
FIG 2 Genes upregulated in response to M. tuberculosis H37Rv TDM at 2 or 24 h were compared for movement over time. (A) The line graph shows the distinct
movement of most of the genes upregulated at 2 h (blue), going back to control levels of expression, while most of the genes upregulated at 24 h (black) were not
upregulated at 2 h. (B) Heat map of genes upregulated at least 1.5-fold at 2 h clustered into 3 groups with regard to expression at 24 h: 1
 downregulated at 24 h, 2

sustained at 24 h, and 3
 further upregulated at 24 h. (C) Heat map of genes upregulated at least 1.5-fold at 24 h also clustered into 3 groups with regard to expression
at 2 h: 1
 further upregulated at 24 h, 2
 upregulated only at 24 h, and 3
 sustained upregulation between 2 and 24 h. Only genes with P values of0.05 are shown.
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(Fig. 7F), no staining was observed. MMP-9, on the other hand,
was detected for as long as 7 days (Fig. 8A). MMP-13 was not
detected at any of the time points examined (data not shown), and
MMP-12 and MMP-14 antibodies suitable for IHC could not be
obtained at the time of this experiment.
Because MMPs can be present in tissues in an inactive state, the
detection of activated MMPs by ISZ is much more informative.
Since MMP-9 was identified as present in TDM bead-induced
granulomas over an extended period, we decided to focus on
MMP-9 for ISZ. ISZ protocols for the detection of activated gela-
tinases (MMP-2 and -9) are also the best described and are based
on the detection of a dye-quenched fluorescent molecule after
cleavage from gelatin. For this set of experiments, the TDM gran-
uloma model had to be modified due to the need for cryosections
and in order to assess MMP-9 activity induced by recruited leu-
kocytes (as opposed to input BMM). In the modified version,
10-m-diameter TDM-coated polystyrene microspheres, which
still elicit an inflammatory reaction (8), were used because 90-
m-diameter microspheres are not amenable to cryosectioning,
no BMM were added, and the mixture was injected into the
subcutis of the scruff of C57BL/6 mice because 10-m-diameter
microspheres will not allow a cohesive matrix to be formed in the
peritoneal cavity and later retrieved. After 7 or 12 days, the matri-
ces were removed and processed for ISZ. Strong fluorescence was
observed at both 7 (Fig. 9A) and 12 (Fig. 9C) days that was medi-
ated primarily by MMP-9, since fluorescence was almost com-
pletely eliminated by the presence of an MMP-9 inhibitor (Fig. 9B
and D). These results show that TDM-induced MMP-9 gene up-
regulation correlates with the presence and activation of MMP-9
within TDM-induced granulomas. Furthermore, TIMP1 induc-
tion by the TDM-coated beads, as observed in our microarray
analysis, was not sufficient to block MMP-9 activity in situ.
MMP-9 and MARCO are also highly upregulated in caseous
human pulmonary TB granulomas. Our observation that TDM
induces the upregulation of MMPs in murine macrophages in
vitro and in situ led us to investigate whether M. tuberculosis infec-
tion affects the regulation of MMP expression in the human host.
For this study, we mined previous data from a genomewide mi-
croarray analysis of caseous granulomas, which represent a histo-
logically defined structure of active TB disease (9). Compared to
uninvolved lung parenchyma, the transcriptional profiles of case-
ous human pulmonary TB granulomas revealed top biological
FIG 3 Genes of particular relevance to the immune response and tissue remodeling from the heat maps shown in Fig. 2 are expanded to show individual genes.
(A) Several growth factors were specifically downregulated at 24 h in response to TDM-coated beads. (B) Genes involved in endocytosis were variably regulated.
(C) Chemokines were also differentially regulated over time, although several, mainly in the CXCL structural group, were upregulated in a sustained fashion. (D) Several
interleukins were upregulated between 2 and 24 h, while IL-10 was specifically downregulated over this period and IL-1 responses were slightly reduced at 24 h
compared to 2 h. (E) Macrophage-associated genes were also differentially regulated over time. A point of interest is the marked upregulation of MARCO at 24 h.
TABLE 3 BMM genes downregulated at least 2-fold in response to
H37Rv TDM-coated beads compared to PG-coated beads at 24 ha
Functional category and gene product Fold change
Immune response
Ndrg1 2.78
Mrc1 2.44
Msr2 3.7
CCR2 2.44
Thbd 2.22
Tissue remodeling
Plau 2.08
Rnase4 2.38
Fn1 2.56
a Data for replicate genes were averaged.
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functions, including cell death, cell-mediated immune response,
tissue morphology, and infection mechanisms. MMP-9 was con-
sistently highly expressed in the TB granulomas, while being un-
detectable in uninvolved regions of the lung. Furthermore, among
differentially regulated genes, MARCO, the macrophage scaven-
ger receptor that interacts with TDM (30), was also highly upregu-
lated in the caseous human pulmonary TB granulomas, while be-
ing undetectable in uninvolved human lung tissue.
Cryosections were also examined for MMP-9 activation, using
DQ-gelatin ISZ. Although there was a high background due to
autofluorescence of the elastin in alveolar septa (Fig. 10C), the
fluorescence intensity was greater in inflamed lesions overlaid
with DQ-gelatin (Fig. 10A) than in those overlaid with gelatin only
(Fig. 10B). These data show that gelatinases (MMP-2 or MMP-9)
are present and active within human TB lesions, consistent with
the microarray data.
In summary, our microarray and ISZ studies of human TB
granulomas clearly demonstrate that tissue remodeling is very ac-
tive in these granulomas at the transcriptional and functional lev-
els, as shown by the upregulation of MMP-9 and cleavage of DQ-
gelatin. These data strongly suggest that TDM might contribute to
the increased secretion of active MMPs within human TB granu-
lomas, and ultimately to the breakdown of the fibrous TB granu-
loma capsule, leading to disease transmission.
DISCUSSION
TDM has been shown to have a variety of immunostimulatory
properties, such as adjuvanticity (40–43) and enhancement of
FIG 4 Most of the immune response genes upregulated in response to TDM are MyD88 dependent. BMM from MyD88-deficient and wild-type mice were
stimulated with TDM-coated microspheres for 24 h, and gene responses were compared to those of resting BMM from the same genotype. (A) Wild-type
BMM showed tremendous up- and downregulation of genes in response to TDM. Black dots indicate genes involved in immune responses. (B) MyD88-
deficient mice showed a muted response to TDM-coated beads, and many of the immune response genes were no longer significantly elevated. Threshold bars
are set at a 2-fold increase and decrease. Only genes with P values of0.05 are shown.
FIG 5 Most of the macrophage genes regulated in response to TDM are MyD88 dependent. BMM genes that were shown to be up- or downregulated in
response to H37Rv TDM after normalization against PG were analyzed in the microarray data acquired by the comparison of MyD88-deficient to wild-type
BMM. Most genes upregulated (A) or downregulated (B) in response to H37Rv TDM were found to be MyD88 dependent.
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nonspecific resistance to a number of infectious agents (44–49).
While mechanisms for the toxic effects of TDM have been studied
in detail, less is known regarding how TDM stimulates macro-
phages to become activated. Our laboratory, the Hunter labora-
tory, and others have shown that the mode of presentation of
TDM is vital to in vitro and in vivo responses (6, 8). Micellar and
phagocytosable forms of TDM elicit minimal macrophage activa-
tion, while oil-water emulsions of TDM and large TDM-coated,
nonphagocytosable particles stimulate strong proinflammatory
cytokine production from macrophages and robust inflammatory
responses in vivo. Since we have previously shown that TDM-
coated 90-m-diameter polystyrene microspheres are immunos-
timulatory for murine BMM in a manner most consistent with
in vivo administration of TDM in emulsions, we decided to study
the regulation of genes during this response in order to better
understand the effect of TDM on macrophages.
Our microarray analyses have shown that TDM presented in
this manner induces a unique set of genes involved in inflamma-
tion, tissue remodeling, and other responses in BMM, in a pre-
dominantly MyD88-dependent manner. These results support
our previous work showing that TDM at least partially signals
through a TLR2 pathway, in association with MARCO and CD14
(30). Comparison of our gene list to genes induced in macro-
phages from the same mouse strain and at the same time point by
lipopolysaccharide (LPS), another ligand that partially signals
through the adaptor molecule MyD88, showed only 7 genes in
common (50). This discrepancy suggests that receptors and path-
ways other than the TLR4-MyD88 pathway are utilized by TDM
on BMM, although other factors, such as the method of LPS
delivery (in solution) and TRIF signaling (the other TLR4 signal-
ing pathway), may also be important. A likely possibility is the
FcR-Syk-Card9 pathway, mediated by the interaction of TDM
FIG 6 The expression of several MMPs is upregulated at 24 h, in a partially
MyD88-dependent manner, in response to stimulation with TDM-coated mi-
crospheres. (A) Heat map of gene upregulation in wild-type compared to
MyD88-deficient BMM in response to stimulation with TDM for 24 h. (B)
Fold upregulation of MMPs in the wild-type versus MyD88-deficient BMM
microarray experiment compared to real-time PCR results. ND, not
determined.
FIG 7 MMP-8 can be detected transiently in TDM-coated bead matrices.
TDM-coated 90-m-diameter microspheres and congenic BMM suspended
in Matrigel were injected into the peritoneal cavities of C57BL/6 mice. At
various time points, the matrices were removed, fixed, and embedded in par-
affin for sectioning and immunohistochemistry. Fourteen-hour-old matrices
showed the strongest staining using anti-MMP-8 antibody (A), and this was
mostly due to macrophages, as matrices removed from neutrophil-depleted
mice still stained strongly (B). (C) An isotype-matched antibody was used as a
negative control. (D) By 36 h, few of the cells clustered around the TDM beads
stained positively for MMP-8, although scattered cells in the loose periphery of
the matrix were positive (E). (F) Very few MMP-8-positive cells remained by 4
days.
FIG 8 Recruited leukocytes in 7-day-old matrices stain strongly for MMP-9.
TDM bead matrices were removed from the peritoneal cavities of mice after 7
days and immunohistochemically stained using anti-MMP-9 antibody. (A)
Most of the leukocytes recruited to the TDM-coated beads (open spaces)
stained strongly for MMP-9. (B) An isotype-matched control antibody was
used as a negative control.
FIG 9 Gelatinase activity in TDM bead granulomas is due primarily to
MMP-9 activation. TDM-coated bead-based matrices were removed from the
subcutis of C57BL/6 mice after 7 (A and B) and 14 (C and D) days. ISZ was
performed on cryosections, using DQ-gelatin as a substrate and a specific
MMP-9 inhibitor that distinguishes between MMP-2 and MMP-9 activities.
Both time points showed strong activity (A and C) based on release of the
fluorescent DQ molecule, which was primarily MMP-9 mediated, as indicated
by markedly reduced fluorescence in the presence of an MMP-9 inhibitor (B
and D).
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with the macrophage C-type lectin receptor Mincle (38). Recent in
vivo infection studies, however, have shown that neither MARCO
nor Mincle is required for control of M. tuberculosis infection in
the mouse model (51, 52), suggesting that there are redundant
pathways through which M. tuberculosis stimulates the host im-
mune response. Upregulation of several cytokines (TNF-, IL-1,
and IL-10) and chemokines (CCL3, CCL4, CCL7, CCL12,
CXCL1, CXCL2, and CXCL10) important in the response to TB at
least partially explains the ability of TDM to induce many of the
lesions and symptoms observed during TB (4, 5, 53–58). Several of
these immune response genes were also shown to be upregulated
by infection withM. tuberculosis both in vitro and in vivo (Table 4)
(59–61). These similarities suggest that TDM likely plays a major
role in the pathogenesis of TB. It is important, however, that dif-
ferences between these lists could be due to differences in time
points, host species, or the presence of many other immuno-
modulators on the surface of M. tuberculosis.
The mechanism by which late-stage TB granulomas cavitate
and rupture is largely unknown. Loss of granuloma regulation by
T lymphocytes plays an important role, since depletion of CD4T
cells during simian immunodeficiency virus infection in ma-
caques results in reactivation of TB (62). Breakdown of the fibrous
capsule, however, would require the activation of matrix metallo-
proteinases, and how this occurs is currently unclear. Microbial
products and other TLR agonists that activate macrophages would
presumably be able to stimulate the upregulation and activation of
MMPs. Furthermore, several MMPs have been shown to be pres-
ent and/or activated in TB. Other mycobacterial components,
such as lipomannan, lipoarabinomannan, and secreted proteins,
induce MMP-9 in monocyte cell lines (17, 25, 63). This is the first
study, however, to link TDM with MMP induction and activation.
Why microbial products that are persistently present would
suddenly induce MMP activation and granuloma cavitation, how-
ever, is currently unknown. For example, MMP-9 has already
been shown to play an important early role in the development of
granulomas during M. tuberculosis infection (64). The depen-
dence of TDM on the mode of presentation for its effects, how-
ever, makes TDM a unique candidate for this kind of differential
immunomodulation. We propose that TDM is relatively immu-
nologically silent during initial infection, since it is presented on
the surface of a 1- to 4-m-long bacillus (65), and our work has
shown that TDM presented on microspheres with a diameter of
10m is not immunostimulatory (8). As a granuloma becomes
more caseous, however, this central debris contains a large
amount of undegraded lipids, which could contain TDM. Fur-
thermore, for currently unknown reasons, late-stage granulomas
often contain M. tuberculosis that resumes active replication, and
virulent M. tuberculosis will form cords due to the presence of
TDM (66). This would present a greater surface area of TDM to
macrophages in the granuloma, rapidly triggering the release of
MMPs that could then break down the fibrous capsule. Microar-
ray analysis of in vivo TDM bead granulomas and caseous human
TB granulomas showed that MMP upregulation occurs in both
scenarios.
In this study, we have shown that TDM can induce and activate
at least MMP-9 in vivo in a granuloma model. In order to prove
our hypothesis, however, we would need to prove that TDM is
present over a large surface area on late-stage granulomas. Poly-
clonal and monoclonal antibodies produced against TDM, how-
ever, are not specific for TDM and recognize other lipids, such as
trehalose monomycolate, from the same species, since these anti-
bodies recognize the mycolic acids, which are not unique to TDM
(data not shown). Lastly, infection models cannot be used to study
the role of TDM in the various stages of the granuloma because
mycobacteria deficient in the enzymes required for TDM biosyn-
thesis are not viable, and the mutant bacteria also do not make
other trehalose mycolates (67–69). It would be very interesting,
however, to follow granuloma development after infection with
the cyclopropane-deficient pcaA mutant strain of M. tuberculosis
in an animal model that develops cavitating granulomas, since this
mutant produces a less immunostimulatory version of TDM (70)
and was shown to be attenuated for up to 130 days in mice, which
typically do not form cavitating lesions in response to infection
(71). Conversely, the cyclopropane-mycolic acid synthase 2
(cmaA2) mutant of M. tuberculosis, which lacks trans-cyclopropa-
nation of mycolic acids and has been shown to be hypervirulent,
may also be interesting to study in a cavitating granuloma model
(72). With the development of better staining methods for M.
tuberculosis, which show that there are more bacteria present in
late-stage granulomas than previously detected by traditional ac-
id-fast stains (73), large aggregates of bacteria presenting TDM
over a large surface area may be detectable.
FIG 10 Human tuberculous pulmonary granulomas show gelatinase activity.
Cryosections of tuberculous lung samples from human patients were exam-
ined by ISZ for gelatinase activity. (A) Gelatinase activity was present within
TB granulomas. (B) In the absence of DQ-gelatin, granulomas were autofluo-
rescent due to the presence of elastin; however, these tissues were not fluores-
cent to the level seen in panel A. (C) Autofluorescence of histologically unre-
markable pulmonary architecture.
TABLE 4 Genes upregulated in response to H37Rv TDM-coated beads
at 2 h were also present at 24 h in infection studiesa
TDM-upregulated
gene product
Presence of product (reference)
M. tuberculosis
infection of C57BL/6
BMM at 24 h (59)
H37Rv infection
of C57BL/6 mice
at 24 h (60)
Human lung
TB infection
(61)
ICAM-1 
IL-1  
IL-1RA 
IER-3 
IRG-1 
IRF-1 
Jun-B 
Nfkbia 
SAA3 
SOD2 
TNF- 
TRAF-1 
a Genes upregulated at least 1.5-fold in response to TDM-coated beads compared to
PG-coated beads at 2 h were compared to gene upregulation in response to infection.
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Future work toward understanding the role of TDM in MMP
activities needs to include the study of MMP regulators, such as
TIMPs. TIMPs form a 1:1 reversible stoichiometric complex with
MMPs, and while TIMP1 can inhibit all MMPs, it is considered
the primary inhibitor for MMP-9 (74–76). TIMP1 has been
shown to be a poor inhibitor of membrane-attached MMP-14
(77), which was especially upregulated in response to TDM (Table
1). Of the MMP inhibitors, however, only TIMP1 was upregulated
by TDM, and ISZ results support the observation that this upregu-
lation was not enough to impair MMP-9 activity.
Overall, TDM elicits a robust inflammatory gene profile in
macrophages that is particularly consistent with responses to M.
tuberculosis infection and may be a key driver of the tissue remod-
eling that occurs during early granuloma formation and late-stage
cavitation. These pathological activities suggest that perhaps mod-
ification of TDM should be considered during attenuated vaccine
design and that prevention of bacterial aggregation may help in
the prevention of cavitation and transmission. Further work is
needed, however, to definitively show the connection between the
form of TDM and granuloma construction and breakdown.
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